The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy
Dana Kim(Goethe University Frankfurt), Zhihong Liu(Chinese Academy of Sciences), Michelle Hladunewich(Sunnybrook Health Science Centre), Ming‐Hui Zhao(China National Petroleum Corporation (China)), Laurent Billot(The George Institute for Global Health), Helen Monaghan(The George Institute for Global Health), Vlado Perkovic(New South Wales Department of Health), Vivekanand Jha(The George Institute for Global Health), Mark Woodward(UNSW Sydney), David W. Johnson(Hennepin County), Muh Geot Wong(FIND), Adeera Levin(University of British Columbia), Heather N. Reich(University Health Network), Tak Mao Chan(Chinese University of Hong Kong), David C. Wheeler(University College London), Jicheng Lv(Ministry of Education of the People's Republic of China), Richard J. Glassock(University of California, Los Angeles), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Jürgen Flöge, Hong Zhang(Peking University), Daniel Cattran(University of Toronto), Meg Jardine(Royal North Shore Hospital), Yangfeng Wu(Peking University), Sana Shan(UNSW Sydney), Sean Barbour, Lai Seong Hooi(Sultanah Aminah Hospital)
Cited by 15
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k